Skip to NavigationSkip to content


AbbVie turns to tau for Alzheimer’s in $1.1bn deal

Sailing against the prevailing winds in the Alzheimer’s disease space, AbbVie has launched a deal worth a potential $1.1 billion with Voyager Therapeutics.

The news is a positive note amongst a fair amount of doom-and-gloom in the hopes of finding a treatment for Alzheimer’s in the near future, perhaps exemplified best by Pfizer’s decision to exit the neuroscience area at the beginning of the year.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches